Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/27334
Başlık: | Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain |
Yazarlar: | Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı. Uludağ Üniversitesi/Veteriner Fakültesi/Patoloji Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Hayvan Yetiştiriciliği, Beslenme ve Et Araştırma Enstitüsü. 0000-0002-3595-6286 Baǧdaş, Deniz Çinkılıç, Nilüfer Özbölük, Hasret Yücel Özyiǧit, Musa Özgür Gürün, Mine Sibel AAR-6478-2021 AAG-8716-2019 AAH-5296-2021 AAH-2873-2021 15062425700 26533892300 55890590200 6507338060 55664349700 |
Anahtar kelimeler: | Pharmacology & pharmacy Antihyperalgesic Chlorogenic acid Chronic constrictive nerve injury Neuropathic pain Rat Oxygen species ros Inflammatory pain Rat Polyphenols |
Yayın Tarihi: | Eki-2013 |
Yayıncı: | Springer |
Atıf: | Bağdaş, D. vd. (2013). "Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain". Journal of Natural Medicines, 67(4), 698-704. |
Özet: | Chlorogenic acid (CGA) is a natural organic phenolic compound that is found in many plants, fruits and vegetables. CGA has beneficial bioactivities and strong therapeutic effects in inflammatory processes. CGA-rich fractions have analgesic activity but CGA has not been tested previously in neuropathic pain, which results from tissue damage, inflammation or injury of the nervous system. Chronic constrictive nerve injury (CCI) is a peripheral neuropathic pain model which initiates an inflammatory cascade. We aimed to determine possible antihyperalgesic effects of CGA in neuropathic pain. Our study showed for the first time that CGA [50, 100 and 200 mg/kg; intraperitoneally (i.p.)] produced significant dose- and time-dependent antihyperalgesic activity in CCI-induced neuropathic pain. In addition, chronic administration of CGA (100 mg/kg/day; i.p. for 14 days) prevented the development of mechanical hyperalgesia and attenuated CCI-induced histopathological changes. On the other hand, CGA (200 mg/kg) did not affect falling latencies of rats in the rota rod test. Hence, CGA might represent a novel potential therapeutic option for the management of neuropathic pain. |
URI: | https://doi.org/10.1007/s11418-012-0726-z https://link.springer.com/article/10.1007/s11418-012-0726-z http://hdl.handle.net/11452/27334 |
ISSN: | 1340-3443 1861-0293 |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.